Fifth Third Bancorp Reduces Stock Position in Repligen Corporation $RGEN

Fifth Third Bancorp lowered its position in shares of Repligen Corporation (NASDAQ:RGEN) by 28.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,088 shares of the biotechnology company’s stock after selling 1,646 shares during the period. Fifth Third Bancorp’s holdings in Repligen were worth $508,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. KBC Group NV boosted its position in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 329 shares during the period. Harvest Fund Management Co. Ltd purchased a new stake in Repligen during the 1st quarter valued at $132,000. XTX Topco Ltd boosted its position in Repligen by 34.2% during the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock valued at $1,646,000 after buying an additional 3,295 shares during the period. GAMMA Investing LLC boosted its position in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 274 shares during the period. Finally, Dynamic Technology Lab Private Ltd boosted its position in Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock valued at $1,172,000 after buying an additional 6,448 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on RGEN shares. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Wells Fargo & Company dropped their target price on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. Finally, Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $168.75.

Repligen Stock Down 1.2%

Shares of Repligen stock opened at $124.09 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The company has a 50-day moving average of $120.41 and a 200 day moving average of $125.34. The firm has a market cap of $6.98 billion, a price-to-earnings ratio of -496.34, a PEG ratio of 2.32 and a beta of 1.07. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.